Can exercise plus a GLP-1 drug boost heart and muscle health in metabolic syndrome?

NCT ID NCT04575844

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether exercise training, the drug liraglutide, or both together can improve blood flow to the heart and muscles and help the body use insulin better in adults with metabolic syndrome. About 80 participants will be randomly assigned to one of four groups: control, exercise only, liraglutide only, or exercise plus liraglutide. They will be monitored for 24 weeks to measure changes in blood vessel function and insulin sensitivity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Liraglutide (a GLP-1 receptor agonist drug) and supervised exercise training

What this could lead to

If successful, this could show that combining exercise with liraglutide improves heart and muscle blood flow and insulin sensitivity better than either alone, pointing to a more effective management strategy for metabolic syndrome.

What could go wrong

This is a relatively small, early-phase trial (80 participants) focused on short-term changes in blood flow and insulin action, not long-term health outcomes. Results may not apply to all people with metabolic syndrome, and liraglutide can cause side effects like nausea or vomiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22906, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••